Immune-Stimulatory Effects of Curcumin on the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma.

NF-κB NF-κB inhibitors Poly I:C curcumin epithelial to mesenchymal transition head and neck squamous cell carcinoma modulation of tumor microenvironment

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
16 Mar 2021
Historique:
received: 20 01 2021
revised: 11 02 2021
accepted: 12 03 2021
entrez: 3 4 2021
pubmed: 4 4 2021
medline: 4 4 2021
Statut: epublish

Résumé

Curcumin is known to have immune-modulatory and antitumor effects by interacting with more than 30 different proteins. An important feature of curcumin is the inhibition of nuclear factor kappa of activated B-cells (NF-κB). Here, we evaluate the potential of curcumin to reverse the epithelial to mesenchymal transition (EMT) of head and neck squamous cell carcinoma (HNSCC) cells as a part of tumor escape mechanisms. We examined the impact of curcumin on the expression of different pro- and antitumoral chemokines in ex vivo HNSCC tumor tissue and primary macrophage cultures. Further, we evaluated the combinatorial effect of curcumin and toll-like receptor 3 (TLR3) agonist Poly I:C (PIC) on NF-κB inhibition and regulatory T-cell (Treg) attraction. Mesenchymal markers were significantly reduced in cancer specimens after incubation with curcumin, with simultaneous reduction of key transcription factors of EMT, Snail, and Twist. Furthermore, a decrease of the Treg-attracting chemokine CCL22 was observed. Additionally, curcumin-related inhibition of NF-κB nuclear translocation was evident. The combination of PIC with curcumin resulted in further NF-κB inhibition, whereas PIC alone contrarily resulted in NF-κB activation. Furthermore, curcumin was more effective in inhibiting PIC-dependent NF-κB activation and Treg attraction compared to known NF-κB inhibitors BAY 11-7082 or caffeic acid phenethyl ester (CAPE). The presented results show, for the first time, the immune-modulating effects of curcumin in HNSCC, with potent inhibition of the Treg-attracting effects of PIC. Hence, curcumin presents a promising drug in cancer therapy as a supplement to already established treatments.

Identifiants

pubmed: 33809574
pii: cancers13061335
doi: 10.3390/cancers13061335
pmc: PMC8001767
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Walter-Schulz Stiftung, Munich, Germany
ID : D.6166

Références

Gastroenterology. 2010 Apr;138(4):1429-40
pubmed: 19909745
Endocrinology. 2005 Mar;146(3):1491-7
pubmed: 15564333
Invest New Drugs. 2019 Oct;37(5):837-848
pubmed: 30465316
Clin Cancer Res. 2013 Mar 15;19(6):1340-6
pubmed: 23271799
Am J Physiol Lung Cell Mol Physiol. 2020 May 1;318(5):L864-L872
pubmed: 32101016
Front Oncol. 2019 Jul 23;9:656
pubmed: 31396482
Oral Oncol. 2011 Sep;47(9):818-26
pubmed: 21745758
Eur J Pharmacol. 2017 Jan 5;794:61-68
pubmed: 27832944
Front Oncol. 2019 Nov 08;9:1100
pubmed: 31788442
Head Neck. 2008 Feb;30(2):251-61
pubmed: 18172882
Clin Exp Immunol. 2018 Oct;194(1):67-78
pubmed: 30229863
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cell Oncol (Dordr). 2019 Aug;42(4):405-421
pubmed: 30980365
Oral Oncol. 2019 Jan;88:29-38
pubmed: 30616794
J Biol Chem. 2007 May 25;282(21):15319-23
pubmed: 17395581
Front Pharmacol. 2019 Jul 30;10:715
pubmed: 31417401
Int Immunopharmacol. 2012 Feb;12(2):368-77
pubmed: 22197802
J Biol Chem. 2005 Jul 1;280(26):24347-55
pubmed: 15860458
Head Neck. 2007 Feb;29(2):120-7
pubmed: 17103408
J Surg Oncol. 2011 May 1;103(6):468-74
pubmed: 21480238
Cancer Res. 2012 May 1;72(9):2162-71
pubmed: 22549946
J Clin Oncol. 2015 Oct 10;33(29):3293-304
pubmed: 26351330
Biotechnol Adv. 2014 Nov 1;32(6):1053-64
pubmed: 24793420
Nat Rev Immunol. 2005 Oct;5(10):749-59
pubmed: 16175180
Pharmacol Ther. 2015 Feb;146:120-31
pubmed: 25281915
Phytother Res. 2018 Jun;32(6):985-995
pubmed: 29480523
Vaccine. 2009 May 26;27(25-26):3401-4
pubmed: 19200817
J Immunother Cancer. 2015 Mar 24;3:6
pubmed: 25806105
Clin Cancer Res. 2008 Jul 15;14(14):4491-9
pubmed: 18628464
Br J Cancer. 2010 Feb 16;102(4):639-44
pubmed: 20087353
Oncoimmunology. 2015 Sep 2;5(3):e1088631
pubmed: 27141345
Int J Biol Macromol. 2019 Jun 1;130:429-436
pubmed: 30797011
Br J Cancer. 2015 Mar 17;112(6):1067-75
pubmed: 25668006
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Cancers (Basel). 2020 Mar 13;12(3):
pubmed: 32183059
Clin Cancer Res. 2007 Feb 15;13(4):1076-82
pubmed: 17317814
Cancers (Basel). 2019 Aug 15;11(8):
pubmed: 31443240
N Engl J Med. 2004 May 6;350(19):1937-44
pubmed: 15128893
J Cell Physiol. 2019 Aug;234(8):12471-12482
pubmed: 30623441
BMC Complement Altern Med. 2006 Mar 17;6:10
pubmed: 16545122
Clin Cancer Res. 2005 Feb 15;11(4):1467-73
pubmed: 15746048
Eur Rev Med Pharmacol Sci. 2018 May;22(9):2564-2571
pubmed: 29771406
J Immunol Methods. 2011 Jun 30;369(1-2):59-68
pubmed: 21513715
Crit Rev Food Sci Nutr. 2017 Sep 2;57(13):2889-2895
pubmed: 26528921
Clin Cancer Res. 2018 Jan 1;24(1):6-13
pubmed: 28751445
Exp Hematol. 2007 Oct;35(10):1495-509
pubmed: 17889719
Anticancer Res. 2015 Dec;35(12):6411-8
pubmed: 26637850
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Oncol. 2014 Sep 20;32(27):2940-50
pubmed: 25154822
Int J Cancer. 2004 Sep 20;111(5):679-92
pubmed: 15252836
J Clin Invest. 1999 Oct;104(8):1041-50
pubmed: 10525042
Anticancer Res. 2001 Jul-Aug;21(4B):2895-900
pubmed: 11712783
Cancer Biol Ther. 2010 Jan;9(1):8-14
pubmed: 19901561
Nat Rev Immunol. 2006 Oct;6(10):715-27
pubmed: 16977338
Nat Immunol. 2006 Feb;7(2):131-7
pubmed: 16424890
Ann N Y Acad Sci. 2009 Aug;1171:436-47
pubmed: 19723087
Cancer Res. 2018 Aug 1;78(15):4292-4302
pubmed: 29853604
Oncotarget. 2015 Feb 20;6(5):2981-91
pubmed: 25671296
J Hepatol. 2015 Sep;63(3):661-9
pubmed: 25937435
Mol Oncol. 2017 Jul;11(7):718-738
pubmed: 28590039
Am J Pathol. 2014 Apr;184(4):1062-1072
pubmed: 24486326

Auteurs

Charlotte Kötting (C)

Department of Otorhinolaryngology, Head and Neck Surgery, University of Ulm, 89070 Ulm, Germany.

Linda Hofmann (L)

Department of Otorhinolaryngology, Head and Neck Surgery, University of Ulm, 89070 Ulm, Germany.

Ramin Lotfi (R)

Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Services Baden-Württemberg-Hessen, 89081 Ulm, Germany.
Institute for Transfusion Medicine, University Hospital Ulm, 89081 Ulm, Germany.

Daphne Engelhardt (D)

Department of Otorhinolaryngology, Head and Neck Surgery, University of Ulm, 89070 Ulm, Germany.

Simon Laban (S)

Department of Otorhinolaryngology, Head and Neck Surgery, University of Ulm, 89070 Ulm, Germany.

Patrick J Schuler (PJ)

Department of Otorhinolaryngology, Head and Neck Surgery, University of Ulm, 89070 Ulm, Germany.

Thomas K Hoffmann (TK)

Department of Otorhinolaryngology, Head and Neck Surgery, University of Ulm, 89070 Ulm, Germany.

Cornelia Brunner (C)

Department of Otorhinolaryngology, Head and Neck Surgery, University of Ulm, 89070 Ulm, Germany.

Marie-Nicole Theodoraki (MN)

Department of Otorhinolaryngology, Head and Neck Surgery, University of Ulm, 89070 Ulm, Germany.

Classifications MeSH